PTK2 and colorectal carcinoma: Our current study shows that pharmacological inhibition of Met had no effect on FAK activation and cell migration and invasion in CRC cells expressing the NRP1 variants and suggests that β1-integrin bypass signaling contributes to FAK activation and renders Met tyrosine kinase inhibitor-resistant in these cells.